Diversigen is a microbiome sequencing and analysis provider run by microbiome scientists. Our mission is to accelerate the entire microbiome industry toward breakthrough discoveries – paving the way for innovation.
Driven. Passionate. Innovative.
President, Molecular Solutions
Kathleen Weber was named Executive Vice President, Business Unit Leader for Molecular Solutions in January 2019 and promoted to President in January 2022. In this role, she has oversight for the commercial, operational and financial performance of the business unit, which is also known as DNA Genotek and includes our Novosanis and Diversigen wholly owned subsidiaries. Kathy joined OraSure in 2012 as the Senior Vice President and General Manager, Consumer Products. Her role evolved from 2012 to 2018 to also include at various points in time managing the Emerging Disease Portfolio and leading the development of OraSure’s corporate strategy. Prior to joining OraSure, Ms. Weber held several senior commercial leadership positions at Pfizer, Johnson and Johnson and Schering–Plough. Ms. Weber began her career in the financial services industry and held various positions in U.S. and global marketing and operations at Chase Manhattan Bank, now part of JP Morgan Chase. Ms. Weber received a B.S. degree in business administration from Georgetown University and earned an M.B.A. from New York University’s Stern School of Business.
Tonya Ward, PHD
SENIOR DIRECTOR, BIOINFORMATICS & LABORATORY OPERATIONS
Tonya Ward is an accomplished microbiome scientist with expertise in molecular biology, next generation sequencing, microbiome informatics and data visualization. Dr. Ward joined CoreBiome, now Diversigen, in 2018 after completing a postdoctoral fellowship in the academic lab of Dr. Knights at the University of Minnesota. Her postdoctoral work included creating tools for microbiome analysis, leading local clinical microbiome research studies and collaborating on numerous multi-center microbiome initiatives. Ward received her Ph.D. in Biochemistry from the University Ottawa where she studied the human milk metagenome and immune proteins in human milk.
Emily Hollister, PHD
Director, R&D, Computational Biology
Dr. Emily Hollister is a microbial ecologist with training in bioinformatics and statistics. Dr. Hollister holds a Bachelor’s degree in Biological and Chemical Sciences from Wells College and a Ph.D. in Molecular and Environmental Plant Sciences from Texas A&M University. She also completed her postdoctoral training in Molecular Microbial Ecology in the Department of Soil & Crop Sciences at Texas A&M University. Her microbiome experience ranges from soils and biofuel production systems to the human microbiome, built environment, and pre-clinical models of disease.
Jafar Hosseinzadeh, MSc
Director of Software Engineering
Jafar Hosseinzadeh is a seasoned technology expert. He has worked in places such as Massachusetts Institute of Technology, Genuity, BBN (Bolt, Beranek and Newman Inc., now Raytheon BBN Technologies), and Boston Children’s Hospital, in a variety of Information Technology and Software Engineering roles. Prior to joining Diversigen, he worked in a small technology company as the Director of Software Development.
Jafar specializes in establishing software development departments utilizing DevOps and Agile Scrum approaches. Jafar is a proponent of data-driven best practices, metrics, and benchmarks. He believes in cloud technology and aims to create a secure and efficient remote workspace.
Jafar establishes the appropriate strategic vision for the organization’s software engineering department, provides technical leadership, support, and mentorship to the department members, creates standardized processes, and SDLC, and establishes standardized tools across the department, and when necessary, across the organization.
Being a true servant leader, Jafar believes in a customer-centric culture. He encourages his team to strive toward developing their products by capturing the voice of internal and external customers. He promotes problem-solving work habits and adaptability that can expedite delivering exceptional products.
Jafar is a passionate believer in cross-functional teams and works hard to establish a positive functioning work environment within the organization. He collaborates effectively with his peers in various departments.
Jafar has a passion for learning and follows new technologies. He believes one cannot stand still, while technology is moving forward; hence he continuously seeks to learn new technologies and follows the latest trends in the industry. Additionally, Jafar encourages his staff to do the same; he provides access to various online learning tools for his team members. The goal is to have deep collective technical knowledge. This goes along with his servant leadership practice.
Jafar Hosseinzadeh holds a master’s degree in Applied Data Science from Syracuse University.
CARLOS MERINO, PHD, MBA
DIRECTOR, PRODUCT MANAGEMENT AND SCIENTIFIC DEVELOPMENT
Carlos holds a Ph.D. in Biochemistry from the UNAM, Mexico, and did his postdoctoral training in genetics and molecular biology at the Max Plank, Germany and McGill University, Canada. Carlos received an Executive MBA from the University of Ottawa. He worked at DNA Genotek and OraSure as Director of Research, Strategy and Innovation. He has led the creation and commercialization of microbiome collection devices and services.
JEAN-PHILIPPE LAINE, PHD
Director of Business Development and Service Coordination
Dr. Laine has 15 years of experience in consultative business development/Sales of enabling technologies supporting Academic Institutions, Pharmaceuticals and Biotechnology companies in their R&D and biomarker discovery efforts.
Prior to joining Diversigen, Dr. Laine has successfully held sales and business development positions with increasing responsibility for mid- to large-size companies focusing on Omics (Metabolomics and Genomics) services across/covering the pre-clinical and clinical pharmaceutical value chain. Dr. Laine led the global business activities at Diversigen Inc., the leader in Microbiome Analysis Services from its inception in 2015 to its acquisition by OraSure Technologies in 2020. At his current position, Dr. Laine is leading the Business Development/Sales team as well as the Service Coordination team. Previous to Diversigen, Dr. Laine was instrumental in the launch of various metabolite-based products in the United States, notably MetaMap®Tox, a database for early assessment/prediction of toxicity and MxP® Quality Control Plasma, an assay testing for pre-analytical errors occurring during plasma generation.
Dr. Laine received his PhD in Molecular Biology with a minor in Immunology and Physiology from the University Louis Pasteur in Strasbourg, France, in collaboration with the National Institute on Aging (NIA) in Baltimore, MD, USA. His Doctorate, Post-Doctoral, and subsequent career resulted in 14 peer-reviewed publications and reviews.
We’re hiring! Join our team!
Diversigen provides services and generates data for research purposes only. Not all services are available in all regions.